T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer
September 27th 2015T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.
Read More